GR3005314T3 - - Google Patents

Info

Publication number
GR3005314T3
GR3005314T3 GR920400697T GR920400697T GR3005314T3 GR 3005314 T3 GR3005314 T3 GR 3005314T3 GR 920400697 T GR920400697 T GR 920400697T GR 920400697 T GR920400697 T GR 920400697T GR 3005314 T3 GR3005314 T3 GR 3005314T3
Authority
GR
Greece
Application number
GR920400697T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3005314T3 publication Critical patent/GR3005314T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR920400697T 1986-11-21 1992-07-30 GR3005314T3 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93347586A 1986-11-21 1986-11-21
US11364387A 1987-10-26 1987-10-26

Publications (1)

Publication Number Publication Date
GR3005314T3 true GR3005314T3 (el) 1993-05-24

Family

ID=26811304

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400697T GR3005314T3 (el) 1986-11-21 1992-07-30

Country Status (5)

Country Link
EP (1) EP0269017B1 (el)
CA (1) CA1321349C (el)
DE (1) DE3780770T2 (el)
ES (1) ES2042529T4 (el)
GR (1) GR3005314T3 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
DE69330285D1 (de) * 1993-03-10 2001-07-05 Univ Yale New Haven Mittel und verfahren zur bleichung der haut
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
WO1995024894A2 (en) * 1994-03-14 1995-09-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
KR20010072957A (ko) * 1998-08-24 2001-07-31 추후보정 Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
US20190070247A1 (en) 2017-09-07 2019-03-07 The Children's Hospital Of Philadelphia Compositions and Methods for Treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) and Other Neurodegenerative Disorders Associated with Aberrant Amyloid Deposits

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526205A (en) * 1974-11-07 1978-09-27 Searle & Co Treatment of interferon-like material
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins

Also Published As

Publication number Publication date
EP0269017A2 (en) 1988-06-01
ES2042529T3 (es) 1993-12-16
EP0269017A3 (en) 1989-06-21
DE3780770T2 (de) 1993-02-25
CA1321349C (en) 1993-08-17
ES2042529T4 (es) 1996-07-16
DE3780770D1 (de) 1992-09-03
JPS63190831A (ja) 1988-08-08
EP0269017B1 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
EP0772999A3 (el)
IN167693B (el)
AU7131891A (el)
IN173489B (el)
IN170755B (el)
IN172043B (el)
IN169471B (el)
GR3005314T3 (el)
IN171229B (el)
AU7354491A (el)
IN171412B (el)
IN164427B (el)
DE3790032T1 (el)
FR2598548B1 (el)
FR2600704B1 (el)
AU6562586A (el)
AU7131791A (el)
JPH0745503B1 (el)
AU5344086A (el)
AU5878886A (el)
IN165066B (el)
AU5783386A (el)
AU5857886A (el)
BE905178A (el)
BE905135A (el)